Sign in

Trial result ·

Risk of drug-induced liver injury in multiple system atrophy patients treated with KM-819 is potentially associated with the HLA-DPB1*05:01:01:01 allele.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study looked at liver harm from a drug called KM-819. KM-819 was tested in Korean people with multiple system atrophy (MSA). It was a phase 2 trial with a dummy drug group for comparison. Then the team looked at the genes of some treated people. They read the full DNA of 16 people who took KM-819.

What they found

Of 34 people on KM-819, 9 had liver harm linked to the drug. An outside expert group made that call. None of the 34 people on the dummy drug had liver harm. Blood for gene tests was there for only 6 of the 9 cases. All 6 of them carried a gene type called HLA-DPB1*05:01:01:01. Only 1 of 10 treated people without liver harm carried it. In this group, the gene type seemed to flag the cases well.

What it means for patients

This gene type may be linked to liver harm from KM-819. The authors see it as a possible risk marker for now. They say it applies only to this Korean group so far. They say it is not yet ready to use for sorting people by risk.

Why it is not certain yet

The gene part of the study used very few people. Blood samples were missing for some of the liver cases. The same group was used to find the marker and to test it. The authors say the results are only a first idea to test further. Larger studies in people of many backgrounds are still needed. The abstract notes wide ranges around its figures.

Source

Risk of drug-induced liver injury in multiple system atrophy patients treated with KM-819 is potentially associated with the HLA-DPB1*05:01:01:01 allele.

PubMed · PMID 42805974

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Multiple system atrophy publications